Drug intelligence / Profile preview

BI 765250

Development stage: Phase 1
Lead developer: Boehringer
Modality: Monoclonal Antibodies → Antibody-Based Therapeutics
Administration: Intravenous, Subcutaneous

Overview

BI 765250 is an investigational drug developed by Boehringer Ingelheim for the treatment of plaque psoriasis. It is administered intravenously or subcutaneously and is currently in phase 1 clinical trials. The drug’s mechanism of action has been described as a signal regulatory protein alpha (SIRPα) inhibitor, representing a novel approach in the treatment of immune-mediated skin disorders such as plaque psoriasis. Clinical studies are focused on evaluating its safety, tolerability, pharmacokinetics, and pharmacodynamics in both healthy volunteers and patients with moderate to severe chronic plaque psoriasis.

Targets

SIRPA (Signal-regulatory protein alpha)

Beyond the preview

Go deeper on BI 765250.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on BI 765250.

Explore the full profile